Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another PPI player

This article was originally published in The Tan Sheet

Executive Summary

Takeda will launch its Rx proton pump inhibitor Kapidex (dexlansoprazole) despite a market filled with OTC alternatives, established brands and low-cost generics. The Japanese firm is banking on the drug's novel dual delayed-release formulation to differentiate it in a field that could soon include a generic version of its own Prevacid (lansoprazole), which Novartis licensed to develop. Takeda will need to market Kapidex in a manner similar to AztraZeneca's launch of Nexium (esomeprazole) when its Prilosec (omeprazole) went generic (1"The Tan Sheet" July 26, 2004, p. 8). The OTC PPI market also is more crowded after Procter & Gamble lost exclusivity for its Prilosec OTC in March 2008 and private label alternatives hit the market. P&G reported declines in Prilosec OTC sales since then, including a double-digit drop in its fiscal 2009 second quarter (2"The Tan Sheet" Feb. 2, 2009, p. 12). Novartis said it is "committed" to launching an OTC Prevacid, but the firm has not discussed the timing of the launch (3"The Tan Sheet" Jan. 19, 2009, p. 3)

You may also be interested in...

Sales & Earnings In Brief

Chattem expects another "very good year": Chattem prepares to roll out at least six new products in 2009 and is "at a tipping point on moving to the next level," the Chattanooga, Tenn.-based company says. CEO and Chairman Zan Guerry explained during a Jan. 29 fourth-quarter earnings call that the firm has "the best new products line-up, the highest scoring advertising on the biggest promotions kicking off in February through June in history," making 2009 likely another strong year. In fiscal 2008, the firm's total revenues grew 7.4 percent to $454.9 million fueled primarily by the addition of brands acquired from Johnson & Johnson. The company's oral care category advanced 29 percent to $62.9 million and internal OTCs were up 7 percent to $48 million in the September-November period. Chattem's net income grew 11 percent to $66.3 million

AstraZeneca Nexium Ad Campaign May Try To Up-Sell Prilosec OTC Patients

AstraZeneca is considering development of a direct-to-consumer ad campaign for Nexium that would target Prilosec OTC users

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts